Designed for discovery of new Nucleoside-like antivirals
3 200 compounds
In spite of significant success in medicine in last decades, development of effective new antiviral agents and vaccines continue to be a challenging task for the modern drug discovery. Viruses share most of the metabolic processes of host cells, thereby making difficult search of selective antiviral agents. However, some enzymes are only present in viruses and these are potential and most attractive targets for antiviral drugs.
For instance, there are several key enzymes, which are involved in the processes with nucleic acids like DNA- and RNA-polymerases. Also, reverse transcriptases possess high potential as antiviral targets. The success of previously approved anti-HCV drug Sofosbuvir has demonstrated the potency of small molecules and the important role of viral RNA-polymerases as drug targets. The series of new drug candidates with nucleoside-like scaffolds introduced by Gilead have shown promising results in treating of serious viral infections such as recently emerged Coronavirus, Ebola and RSV.
Typical Formats
Antiviral Library is available for supply in various pre-plated formats, including the following most popular ones:
Catalog No.
AVR-3200-0-Z-10
Compounds
3 200
3 plates
Amount
≤ 300 nL of 10 mM of DMSO solutions
Plates and formats
1536-well Echo LDV microplates, first and last four columns empty, 1280 compounds per plate
Price
Catalog No.
AVR-3200-10-Y-10
Compounds
3 200
10 plates
Amount
≤ 10 µL of 10 mM DMSO solutions
Plates and formats
384-well, Echo Qualified LDV microplates #001-12782 (LP-0200), first and last two columns empty, 320 compounds per plate
Price
Catalog No.
AVR-3200-50-Y-10
Compounds
3 200
10 plates
Amount
50 μL of 10 mM DMSO solutions
Plates and formats
384-well, Greiner Bio-One plates #781280, 1,2 and 23,24 columns empty, 320 compounds per plate
Price
Catalog No.
Library & follow-up package
Plates and formats
AVR-3200-10-Y-10 screening library 3 200 cmpds, hit resupply, analogs from 4.4M+ stock and synthesis from REAL Space
Price
*We will be happy to provide our library in any other most convenient for your project format. Please select among the following our standard microplates: Greiner Bio-One 781270, 784201, 781280, 651201 or Echo Qualified 001-12782 (LP-0200), 001-14555 (PP-0200), 001-6969 (LP-0400), C52621 or send your preferred labware. Compounds pooling can be provided upon request.
Download SD file
Examples of nucleoside mimetics as antiviral agents
Remdesivir
Ebola, Junin and MERS viruses
studied against Coronaviruses, 2019-nCoV
Sofosbuvir
Hepatitis C
Entacavir
Hepatitis B virus
Galidesivir
Ebola & Marburg viruses
Ribavirin
RSV infection, hemorrhagic fevers
To meet growing needs in new antivirals Enamine has designed the library of nucleoside-like small molecules, enriched with recently synthesized series of nucleoside-like compounds. The library of carefully selected 3 200 compounds has been pre-plated for most convenient access and prompt delivery in various customized formats.
Library design
Analyzing the structures of known inhibitors we found that most of them are AVR-3200 side mimetics which are not distinguished from the nucleosides by virus enzymes in the active site.
Therefore taking into account pharmacophores and topology of nucleosides and reported nucleoside-like antiviral agents we carefully selected the set of Nucleoside mimetics from our screening collection. The compounds from the set contain natural-like moieties and diverse heterocycles as bioisosters of nucleosides. Additionally, special emphasis has been made on compounds that possess several H-bond donors and potentially can form similar interactions with the protein nucleoside-binding sites as a native nucleoside.
Examples of representative compounds from Antiviral Library
Molecular Profile of the library
Selected compounds have attractive drug/lead-like physical chemical and structural properties that are characteristic for nucleosides and their mimetics: MW 150…400, ClogP -2…4; TPSA <150, RotBonds <7; HBD 1…5, HBA 1…7.
The library is considered to be a convenient starting point for a wide range of antiviral drug discovery projects.
